Humalog Den europeiske union - ungarsk - EMA (European Medicines Agency)

humalog

eli lilly nederland b.v. - lispro inzulin - diabetes mellitus - cukorbetegségben szedett gyógyszerek - a felnőttek és a gyermekek a cukorbetegség kezelésére, akiknek szükségük van a normális glükóz-homeosztázis fenntartásához az inzulin. a humalog a cukorbetegség kezdeti stabilizálására is fel van tüntetve.

Humalog Den europeiske union - portugisisk - EMA (European Medicines Agency)

humalog

eli lilly nederland b.v. - insulina lispro - diabetes mellitus - drogas usadas em diabetes - para o tratamento de adultos e crianças com diabetes mellitus que necessitam de insulina para a manutenção da homeostase normal da glicose. humalog também é indicado para a estabilização inicial do diabetes mellitus.

Humalog Den europeiske union - dansk - EMA (European Medicines Agency)

humalog

eli lilly nederland b.v. - insulin lispro - diabetes mellitus - narkotika anvendt i diabetes - til behandling af voksne og børn med diabetes mellitus, der kræver insulin til opretholdelse af normal glukose homøostase. humalog er også indiceret til den indledende stabilisering af diabetes mellitus.

Humalog Den europeiske union - tysk - EMA (European Medicines Agency)

humalog

eli lilly nederland b.v. - insulin lispro - diabetes mellitus - drogen bei diabetes verwendet - zur behandlung von erwachsenen und kindern mit diabetes mellitus, die insulin zur aufrechterhaltung einer normalen glucosehomöostase benötigen. humalog ist auch zur initialen stabilisierung von diabetes mellitus indiziert.

Humalog Den europeiske union - fransk - EMA (European Medicines Agency)

humalog

eli lilly nederland b.v. - l'insuline lispro - diabète sucré - les médicaments utilisés dans le diabète - pour le traitement des adultes et des enfants atteints de diabète sucré qui ont besoin d'insuline pour le maintien de l'homéostasie normale du glucose. humalog est également indiqué pour la stabilisation initiale du diabète sucré.

Humalog Den europeiske union - engelsk - EMA (European Medicines Agency)

humalog

eli lilly nederland b.v. - insulin lispro - diabetes mellitus - drugs used in diabetes - for the treatment of adults and children with diabetes mellitus who require insulin for the maintenance of normal glucose homeostasis. humalog is also indicated for the initial stabilisation of diabetes mellitus.

HUMALOG KWIKPEN 200 UML Israel - engelsk - Ministry of Health

humalog kwikpen 200 uml

eli lilly israel ltd, israel - insulin lispro - solution for injection - insulin lispro 200 u/ml - insulin lispro - for the treatment of adults with diabetes mellitus who require insulin for the maintenance of normal glucose homeostasis. humalog kwikpen 200 units/ml is also indicated for the initial stabilisation of diabetes mellitus.

HUMALOG- insulin lispro injection, solution USA - engelsk - NLM (National Library of Medicine)

humalog- insulin lispro injection, solution

remedyrepack inc. - insulin lispro (unii: gfx7qis1ii) (insulin lispro - unii:gfx7qis1ii) - humalog is a rapid acting human insulin analog indicated to improve glycemic control in adults and children with diabetes mellitus. humalog is contraindicated: - during episodes of hypoglycemia - in patients who are hypersensitive to humalog or to any of its excipients. pregnancy category b. all pregnancies have a background risk of birth defects, loss, or other adverse outcome regardless of drug exposure. this background risk is increased in pregnancies complicated by hyperglycemia and may be decreased with good metabolic control. it is essential for patients with diabetes or history of gestational diabetes to maintain good metabolic control before conception and throughout pregnancy. in patients with diabetes or gestational diabetes insulin requirements may decrease during the first trimester, generally increase during the second and third trimesters, and rapidly decline after delivery. careful monitoring of glucose control is essential in these patients. therefore, female patients should be advised to tell

HUMALOG- insulin lispro injection, solution USA - engelsk - NLM (National Library of Medicine)

humalog- insulin lispro injection, solution

remedyrepack inc. - insulin lispro (unii: gfx7qis1ii) (insulin lispro - unii:gfx7qis1ii) - humalog is a rapid acting human insulin analog indicated to improve glycemic control in adults and children with diabetes mellitus. humalog is contraindicated: - during episodes of hypoglycemia - in patients who are hypersensitive to humalog or to any of its excipients. risk summary the limited available data with humalog in pregnant women are insufficient to inform a drug-associated risk of adverse developmental outcomes. published studies with insulin lispro used during pregnancy have not reported an association between insulin lispro and the induction of major birth defects, miscarriage, or adverse maternal or fetal outcomes (see data) . there are risks to the mother and fetus associated with poorly controlled diabetes in pregnancy (see clinical considerations) . pregnant rats and rabbits were exposed to insulin lispro in animal reproduction studies during organogenesis. no adverse effects on embryo/fetal viability or morphology were observed in offspring of rats exposed t

HUMALOG- insulin lispro injection, solution
HUMALOG KWIKPEN- insulin lispro injection, solution
HUMALOG JUNIOR KWIKPEN- insuli USA - engelsk - NLM (National Library of Medicine)

humalog- insulin lispro injection, solution humalog kwikpen- insulin lispro injection, solution humalog junior kwikpen- insuli

eli lilly and company - insulin lispro (unii: gfx7qis1ii) (insulin lispro - unii:gfx7qis1ii) - insulin lispro 100 [iu] in 1 ml - humalog is indicated to improve glycemic control in adult and pediatric patients with diabetes mellitus. humalog is contraindicated: - during episodes of hypoglycemia [see warnings and precautions (5.3)] . - in patients who are hypersensitive to insulin lispro or to any of the excipients in humalog [see warnings and precautions (5.5)] . risk summary published studies with insulin lispro used during pregnancy have not reported an association between insulin lispro and the induction of major birth defects, miscarriage, or adverse maternal or fetal outcomes (see data) . there are risks to the mother and fetus associated with poorly controlled diabetes in pregnancy (see clinical considerations) . pregnant rats and rabbits were exposed to insulin lispro in animal reproduction studies during organogenesis. no adverse effects on embryo/fetal viability or morphology were observed in offspring of rats exposed to insulin lispro at a dose approximately 3 times the human subcutaneous dose of 1 unit insulin lispro/kg/day.